GLIPIQ is the Glenmark semaglutide injection brand launched in India on March 21, 2026 for type 2 diabetes. Its main distinguishing feature is the company’s explicit description of two presentations: a multi-dose vial to be used with dose-specific syringes, and a prefilled injection pen. That is different from assuming every Indian semaglutide injection is supplied in the same pen format.
Glenmark’s launch described 2 mg/1.5 mL, 4 mg/3 mL and 8 mg/3 mL strengths and referred to CDSCO approval after an Indian Phase III study. Those figures identify products and concentrations; they are not instructions to measure or administer a dose. The vial-versus-pen distinction is useful for comparing devices, pharmacy verification and packaging, not for do-it-yourself injection techniques.
GLIPIQ’s Indian authorization does not permit U.S. sellers to advertise it as an FDA-approved generic Ozempic. This profile documents source-backed product details and links to the Indian brand directory and FDA-approved American product list without encouraging an unapproved import.
Glenmark announced GLIPIQ as a semaglutide treatment for type 2 diabetes in India. The company stated that the product obtained CDSCO approval following a multicenter randomized, comparative, active-controlled open-label Phase III study conducted in India. This establishes the company’s stated indication, launch context and evidence category, not a general finding of equivalent outcomes across all global semaglutide products.
A manufacturer press release is a reliable starting point for describing its own product, but detailed protocol, labeling and product quality information should be evaluated from their appropriate sources. It cannot establish current pharmacy inventory or authorize international shipping to U.S. patients.
GLIPIQ’s vial presentation was described as requiring dose-specific syringes, while the company also announced pre-filled pens. The two configurations have different components and verification needs. A vial label should be checked for concentration and package information; a pen should be checked for its own integrated administration system. None of those checks is a substitute for licensed professional instruction.
The comparison matters because a seller can inaccurately use “GLIPIQ pen” to describe a vial-based product or omit the supplied syringe/device details entirely. A reader should ask the Indian clinical or dispensing professional for the precise authorized pack. Our Semaglyn profile describes a different company’s cartridge-and-reusable-pen technology.
The manufacturer listed these strengths for both vial and pen configurations in its March launch statement. The paired mass-and-volume numbers describe product presentations and concentration; they are not a prescribed single administration dose. They should not be converted into syringe markings, injection steps or equivalencies with U.S. brand packaging by a shopping page.
A complete product check records the exact combination of strength, volume, presentation, label and permitted local use. Two products containing the same amount of semaglutide in a package can still differ in device architecture and approved instructions. Consumer photos are not enough to establish safe interchangeability.
Glenmark referred to an Indian comparative Phase III study and announced a support initiative named Sankalp. The company’s claims are dated and should not be transformed into an objective ranking of GLIPIQ against every foreign semaglutide brand. A named patient support initiative does not demonstrate universal enrollment, eligibility, or continuing operation at a specific location.
Similarly, the advertised India launch pricing for vials is not an up-to-date U.S. price or evidence that any third-party seller is licensed. This guide intentionally preserves those boundaries. Current clinical eligibility, local availability and the relevant pack would require verification in the appropriate jurisdiction.
Glenmark Pharmaceuticals publicly announced GLIPIQ itself on March 21, 2026. That establishes a branded company-to-product relationship and the company’s own report of Indian approval, rather than proving the legal identity of every contract manufacturing site involved in an individual shipment.
Glenmark also described its Sankalp patient support program in the same release. The existence of an announced support initiative does not certify a particular retailer as a Glenmark distributor or establish enrollment and affordability terms for every Indian patient.
The strongest GLIPIQ identity marker is the dual vial-and-prefilled-pen launch. By contrast, Semaglyn is associated with a cartridge/reusable-device program described by Zydus, and Obeda was described by Dr. Reddy’s in disposable prefilled pens. Those differences are product-identification facts rather than clinical rankings.
Comparisons should keep the product concentrations and devices separate. In particular, the presence of a multi-dose vial in GLIPIQ’s range does not mean that a U.S. branded semaglutide pen can be reused with it or that the company’s dose-specific syringes match another product.
The March company statement places GLIPIQ in India’s type 2 diabetes context and describes CDSCO approval following a multicenter Indian Phase III study. The release reports 2 mg/1.5 mL, 4 mg/3 mL and 8 mg/3 mL configurations across its two stated formats; these are package specifications, not patient instructions.
To verify a particular GLIPIQ product, record both total labeled quantity and device type together with the India-specific pack and local approval document. The same numbers on an unrelated importer’s website do not prove that the item shown belongs to a lawful supply chain.
Nothing in Glenmark’s India launch gives GLIPIQ a U.S. marketing application or permits routine online U.S. dispensing as "generic Ozempic." FDA-approved products in the United States have their own identifiable applications and labels, and an India-market vial does not become an FDA-approved semaglutide vial merely because Glenmark also has U.S. business operations.
If a U.S.-facing site offers GLIPIQ, readers should check the drug’s U.S. application status rather than treating corporate reputation or an Indian approval as authorization. The imported-products guide explains that separate legal issue without directing a purchase.
Vials with dose-specific syringes and prefilled pens can involve different steps, component identifiers and labeling. For a GLIPIQ vial, the concentration, syringe supplied or prescribed and instructions are product-specific. For a GLIPIQ pen, its prefilled device and local instructions need independent checking.
This article intentionally does not calculate syringe units or injection volumes. Similar-looking semaglutide devices can have different specifications, and consumers should seek instruction from the relevant licensed health professional in the jurisdiction where the product is authorized.
The source anchor for GLIPIQ’s reported product design is Glenmark’s March 21, 2026 corporate release. That announcement confirms the company’s descriptions at launch; it is not an independent market survey or an October 2026 stock report. A later package revision or device change should be documented before updating the table.
Distinguish three levels of evidence: the dated corporate release for the company’s launch claim, actual India-authorized product labeling for a specific presentation, and U.S. FDA drug records for any U.S. approval claim. No one source answers all three questions.
The table below is organized around GLIPIQ’s two announced formats and their Indian regulatory context. Its purpose is to keep vial-and-syringe documentation separate from prefilled-pen identification, not to suggest an approved U.S. purchase route.
If a marketplace entry differs from the March 2026 GLIPIQ announcement, verify the change with Indian product labeling or a newer company statement; do not conclude that an image or price proves current authenticity.
| Check | Documented information | What it does not establish |
|---|---|---|
| Trade name | GLIPIQ | Glenmark |
| Indian indication | Type 2 diabetes | Company March 21, 2026 announcement |
| Formats | Multi-dose vial plus prefilled pen | Do not assume device equivalence |
| Reported concentrations | 2 mg/1.5 mL; 4 mg/3 mL; 8 mg/3 mL | Not individual injection doses |
| U.S. authorization | Not established by India launch | Check FDA separately |
This profile was checked against the Glenmark March 21, 2026 GLIPIQ announcement and U.S. FDA product-approval principles as of October 19, 2026. It does not independently certify Sankalp enrollment, product batches, retail stock or cross-border import permission. Indian company claims remain attributed to the releasing company.
This independent site does not sell or import GLIPIQ. Any sponsored or affiliate relationship for other lawful U.S. offers must be identified alongside the particular outbound commercial link; no paid relationship establishes U.S. regulatory approval or medical equivalence.
GLIPIQ is Glenmark’s Indian semaglutide injection brand introduced for type 2 diabetes in March 2026.
The March 2026 company announcement describes both vial and prefilled-pen presentations.
Glenmark listed 2 mg/1.5 mL, 4 mg/3 mL and 8 mg/3 mL product presentations.
No. Product concentration is not personalized administration guidance; a qualified professional and official instructions are needed.
An Indian CDSCO authorization does not establish FDA approval for GLIPIQ in the United States.
The company identified type 2 diabetes in its March 2026 launch statement.
Glenmark described Sankalp as a patient support program in its Indian launch release; current terms and eligibility require independent verification.
No cross-product compatibility should be assumed or attempted.
No. Launch-era price statements do not establish current stock, seller legitimacy or an individual payable amount.